Search

Your search keyword '"Masson-Lecomte, A."' showing total 229 results
Start Over Author "Masson-Lecomte, A." Publisher elsevier bv
229 results on '"Masson-Lecomte, A."'

1. Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

Author

Mertens, L.S., primary, Bruins, H.M., additional, Contieri, R., additional, Babjuk, M., additional, Bhavan, R., additional, Carrion Puig, A., additional, Dominguez Escrig, J.L., additional, Gontero, P., additional, Van Der Heijden, A.G., additional, Liedberg, F., additional, Mariappan, P., additional, Masson-Lecomte, A., additional, Meijer, R.P., additional, Mostafid, H., additional, Neuzillet, Y., additional, Pradere, B., additional, Van Rhijn, B.W.G., additional, Roupret, M., additional, Seisen, T., additional, Soria, F., additional, Viktor, S., additional, Thalmann, G., additional, Xylinas, E., additional, and Witjes, F., additional

Published
2024
Full Text
View/download PDF

2. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study

Author

Gontero, P., primary, Soria, F., additional, Babjuk, M., additional, Burger, M., additional, Comperat, E., additional, Mostafid, H., additional, Palou Redorta, J., additional, Roupret, M., additional, Van Rhijn, B.W., additional, Zigeuner, R., additional, Shariat, S.F., additional, Cohen, D., additional, Masson-Lecomte, A., additional, Xylinas, E., additional, Mariappan, P., additional, Rai, B.P., additional, Capoun, O., additional, Soukup, V., additional, Thalmann, G., additional, Pradere, B., additional, Seisen, T., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, and Sylvester, R.J., additional

Published
2024
Full Text
View/download PDF

3. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer

Author

Contieri, R., primary, Beijert, I., additional, Martini, A., additional, Camperat, E.M., additional, Hernandez, V., additional, Bruins, H.M., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Cohen, D., additional, Mostafid, H., additional, Shariat, S.F., additional, Roupret, M., additional, Pradere, B., additional, Zigeuner, R., additional, Soria, F., additional, Soukup, V., additional, Palou Redorta, J., additional, Capoun, O., additional, Burger, M., additional, Gontero, P., additional, Sylvester, R., additional, Mertens, L., additional, and Van Rhijn, B.W.G., additional

Published
2024
Full Text
View/download PDF

4. Patients non répondeurs au BCG

Author

Leon, Priscilla, primary, Pradère, Benjamin, additional, Neuzillet, Yann, additional, Bajeot, Anne Sophie, additional, Marcq, Gautier, additional, Prost, Doriane, additional, Thibault, Constance, additional, Xylinas, Evanguelos, additional, Allory, Yves, additional, Audenet, François, additional, Masson-Lecomte, Alexandra, additional, Seisen, Thomas, additional, Rouprêt, Morgan, additional, and Roumiguié, Mathieu, additional

Published
2024
Full Text
View/download PDF

6. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, and Michelle R. Downes

Subjects
Urology
Published
2023
Full Text
View/download PDF

9. Transcriptomic profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures

Author

Fontugne, Jacqueline, primary, Xylinas, Evanguelos, additional, Krucker, Clémentine, additional, Dixon, Victoria, additional, Groeneveld, Clarice S., additional, Pinar, Ugo, additional, Califano, Gianluigi, additional, Bucau, Margot, additional, Verine, Jérôme, additional, Desgrandchamps, François, additional, Hermieu, Jean-François, additional, Radvanyi, François, additional, Allory, Yves, additional, and Masson-Lecomte, Alexandra, additional

Published
2023
Full Text
View/download PDF

10. Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database

Author

Pignot, G., primary, Baboudjian, M., additional, Masson-Lecomte, A., additional, Lebacle, C., additional, Tillou, X., additional, Waeckel, T., additional, Duperron, C., additional, Monges, A., additional, Alezra, E., additional, Irani, J., additional, Lechevallier, E., additional, Gravis, G., additional, and Walz, J., additional

Published
2023
Full Text
View/download PDF

15. Do current definitions of BCG failure/ BCG unresponsive NMIBCs correlate with disease progression? Results of an individual patient data validation international multi-center retrospective study

Author

P. Gontero, F. Soria, M. Babjuk, M. Burger, E.M. Comperat, H. Mostafid, J. Palou Redorta, M. Roupret, B.W. Van Rhijn, R. Zigeuner, S.F. Shariat, D. Cohen, A. Masson-Lecomte, V. Hernandez, E. Xylinas, O. Capoun, G. Thalmann, B. Pradere, E. Linares, V. Soukup, T. Seisen, J. Dominguez-Escrig, F. Liedberg, and R.J. Sylvester

Subjects
Urology
Published
2023
Full Text
View/download PDF

17. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Beijert, Irene J., primary, Cheng, Liang, additional, Liedberg, Fredrik, additional, Plass, Karin, additional, Williamson, Sean R., additional, Gontero, Paolo, additional, Ribal, Maria J., additional, Babjuk, Marko, additional, Black, Peter C., additional, Kamat, Ashish M., additional, Algaba, Ferran, additional, Berman, David M., additional, Hartmann, Arndt, additional, Masson-Lecomte, Alexandra, additional, Rouprêt, Morgan, additional, Lopez-Beltran, Antonio, additional, Samaratunga, Hemamali, additional, Shariat, Shahrokh F., additional, Mostafid, A. Hugh, additional, Varma, Murali, additional, Shen, Steven, additional, Burger, Maximilian, additional, Tsuzuki, Toyonori, additional, Palou, Joan, additional, Compérat, Eva M., additional, Sylvester, Richard J., additional, van der Kwast, Theo H., additional, van Rhijn, Bas W.G., additional, and Downes, Michelle R., additional

Published
2023
Full Text
View/download PDF

18. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum

Author

Beijert, Irene J., primary, Hentschel, Anouk E., additional, Bründl, Johannes, additional, Compérat, Eva M., additional, Plass, Karin, additional, Rodríguez, Oscar, additional, Subiela Henríquez, Jose D., additional, Hernández, Virginia, additional, de la Peña, Enrique, additional, Alemany, Isabel, additional, Turturica, Diana, additional, Pisano, Francesca, additional, Soria, Francesco, additional, Čapoun, Otakar, additional, Bauerová, Lenka, additional, Pešl, Michael, additional, Bruins, H. Maxim, additional, Runneboom, Willemien, additional, Herdegen, Sonja, additional, Breyer, Johannes, additional, Brisuda, Antonin, additional, Calatrava, Ana, additional, Rubio-Briones, José, additional, Seles, Maximilian, additional, Mannweiler, Sebastian, additional, Bosschieter, Judith, additional, Kusuma, Venkata R.M., additional, Ashabere, David, additional, Huebner, Nicolai, additional, Cotte, Juliette, additional, Mertens, Laura S., additional, Claps, Francesco, additional, Masson-Lecomte, Alexandra, additional, Liedberg, Fredrik, additional, Cohen, Daniel, additional, Lunelli, Luca, additional, Cussenot, Olivier, additional, El Sheikh, Soha, additional, Volanis, Dimitrios, additional, Côté, Jean-François, additional, Rouprêt, Morgan, additional, Haitel, Andrea, additional, Shariat, Shahrokh F., additional, Mostafid, A. Hugh, additional, Nieuwenhuijzen, Jakko A., additional, Zigeuner, Richard, additional, Dominguez-Escrig, Jose L., additional, Hacek, Jaromir, additional, Zlotta, Alexandre R., additional, Burger, Maximilian, additional, Evert, Matthias, additional, Hulsbergen-van de Kaa, Christina A., additional, van der Heijden, Antoine G., additional, Kiemeney, Lambertus A.L.M., additional, Soukup, Viktor, additional, Molinaro, Luca, additional, Gontero, Paolo, additional, Llorente, Carlos, additional, Algaba, Ferran, additional, Palou, Joan, additional, N'Dow, James, additional, Ribal, Maria J., additional, van der Kwast, Theo H., additional, Babjuk, Marko, additional, Sylvester, Richard J., additional, and van Rhijn, Bas.W.G., additional

Published
2023
Full Text
View/download PDF

19. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway

Author

T.-R. Dobé, Y. Belhadj, C. Michel, M. Djouadou, A. Bouchardi, C. Liron, C. Bento, A. Aregui, P. Meria, A. Thevenot, B. Plaud, S. Culine, P. Mongiat-Artus, F. Desgrandchamps, and A. Masson-Lecomte

Subjects
Postoperative Complications, Urinary Bladder Neoplasms, Urology, Urinary Bladder, Humans, Cystectomy, Neoadjuvant Therapy, Retrospective Studies
Abstract

The effect of ERAS protocols in a population of radical cystectomy (RC) patients fit for neoadjuvant chemotherapy has not been specifically explored.To compare perioperative outcomes of open RC according to the application of an ERAS protocol in a population of patients treated by cisplatin-based NAC.All consecutive patients treated by NAC and RC between 2016 and 2019 were included. The ERAS pathway was implemented in June 2018 and followed the EAU recommendations. All data were prospectively collected. Patients' characteristics, operative outcomes, length of stay (LOS), complication rate according to Clavien-Dindo and pathological results were compared between pre- and post-ERAS. Statistical analysis was performed using R.In total, 79 patients were included, 29 in the ERAS group and 50 in the non-ERAS group. A median number of 19 out of 22 ERAS criteria were followed. Mean number of NAC cycles was 4.45 vs. 4.79 in the pre- and post-ERAS groups respectively (P=0.24). Median time between NAC and RC was 3.8months. Thirty-eight percent vs. 48% of patients received an ileal neobladder in the pre- and post-ERAS group respectively (P=0.51). No differences were observed regarding operative time, blood loss or operative transfusion rates. LOS was drastically reduced in the ERAS period (18.94 vs. 12.10days, P0.001) as well as major (Clavien 2) complications rate (65% vs. 28%, P=0.004).ERAS drastically reduced the LOS and the rate of high-grade complications and can be effectively applied to patients receiving NAC without delaying RC.

Published
2022
Full Text
View/download PDF

20. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

Author

P. Leon, F. Saint, F. Audenet, M. Roumiguié, Y. Allory, Y. Loriot, A. Masson-Lecomte, B. Pradère, T. Seisen, O. Traxer, E. Xylinas, M. Roupret, and Y. Neuzillet

Subjects
Urology
Published
2022
Full Text
View/download PDF

21. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

I.J. Beijert, A.E. Hentschel, J. Bründl, E.M Compérat, K. Plass, O. Rodríguez, J.D. Subiela Henríquez, V. Hernández, E. De La Peña, I. Alemany, D. Turturica, F. Pisano, F. Soria, O. Čapoun, L. Bauerová, M. Pešl, H.M. Bruins, W. Runneboom, S. Herdegen, J. Breyer, A. Brisuda, A. Calatrava, J.. Rubio-Briones, M. Seles, S. Mannweiler, J. Bosschieter, V.R.M. Kusuma, D. Ashabere, N. Huebner, J. Cotte, L.S Mertens, A. Masson-Lecomte, F. Liedberg, D. Cohen, L. Lunelli, O. Cussenot, S. El Sheikh, D. Volanis, J. Côté, M. Rouprêt, A. Haitel, S.F. Shariat, A.H. Mostafid, J.A. Nieuwenhuijzen, R. Zigeuner, J.L. Dominguez-Escrig, J. Hacek, A.R. Zlotta, M. Burger, M. Evert, C.A. Hulsbergen - Van De Kaa, A.G. Van Der Heijden, L.A.L.M. Kiemeney, V. Soukup, L. Molinaro, P. Gontero, C. Llorente, F. Algaba, J. Palou, J. N’Dow, M.J. Ribal, T.H. Van Der Kwast, M. Babjuk, R.J. Sylvester, and B.W.G. Van Rhijn

Subjects
Urology
Published
2022
Full Text
View/download PDF

23. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Author

Morgan Rouprêt, Viktor Soukup, Richard Sylvester, Eva Compérat, Bas W.G. van Rhijn, Fredrik Liedberg, Thomas Seisen, A. Hugh Mostafid, Marko Babjuk, Maximilian Burger, Daniel Cohen, Otakar Čapoun, Joan Palou, Paolo Gontero, Alexandra Masson-Lecomte, José Luis Dominguez Escrig, and Shahrokh F. Shariat

Subjects
Male, medicine.medical_specialty, Bacillus Calmette-Guerin (BCG), Urology, medicine.medical_treatment, Context (language use), Guidelines, Intravesical chemotherapy, Cystectomy, BCG unresponsive, Bladder cancer, Cystoscopy, Diagnosis, European Association of Urology (EAU), Follow-up, Prognosis, Radical cystectomy, Transurethral resection (TUR), Urothelial carcinoma, Administration, Intravesical, BCG Vaccine, Female, Humans, Neoplasm Invasiveness, Carcinoma in Situ, Urinary Bladder Neoplasms, medicine, Chemotherapy, medicine.diagnostic_test, Intravesical, business.industry, Carcinoma in situ, Evidence-based medicine, Guideline, medicine.disease, Administration, business
Abstract

Context The European Association of Urology (EAU) has released an updated version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To present the 2021 EAU guidelines on NMIBC. Evidence acquisition A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines since the 2020 version was performed. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis Tumours staged as Ta, T1 and carcinoma in situ (CIS) are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of tissue obtained via transurethral resection of the bladder (TURB) for papillary tumours or via multiple bladder biopsies for CIS. For papillary lesions, a complete TURB is essential for the patient’s prognosis and correct diagnosis. In cases for which the initial resection is incomplete, there is no muscle in the specimen, or a T1 tumour is detected, a second TURB should be performed within 2–6 wk. The risk of progression may be estimated for individual patients using the 2021 EAU scoring model. On the basis of their individual risk of progression, patients are stratified as having low, intermediate, high, or very high risk, which is pivotal to recommending adjuvant treatment. For patients with tumours presumed to be at low risk and for small papillary recurrences detected more than 1 yr after a previous TURB, one immediate chemotherapy instillation is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose intravesical bacillus Calmette-Guerin (BCG) immunotherapy or instillations of chemotherapy for a maximum of 1 yr. For patients with high-risk tumours, full-dose intravesical BCG for 1–3 yr is indicated. For patients at very high risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is also recommended for BCG-unresponsive tumours. The extended version of the guidelines is available on the EAU website at https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ . Conclusions These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. Patient summary The European Association of Urology has released updated guidelines on the classification, risk factors, diagnosis, prognostic factors, and treatment of non–muscle-invasive bladder cancer. The recommendations are based on the literature up to 2020, with emphasis on the highest level of evidence. Classification of patients as having low, intermediate, or and high risk is essential in deciding on suitable treatment. Surgical removal of the bladder should be considered for tumours that do not respond to bacillus Calmette-Guerin (BCG) treatment and tumours with the highest risk of progression.

Published
2022
Full Text
View/download PDF

24. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Author

Morgan Rouprêt, Thomas Seisen, Alison J. Birtle, Otakar Capoun, Eva M. Compérat, José L. Dominguez-Escrig, Irene Gürses Andersson, Fredrik Liedberg, Paramananthan Mariappan, A. Hugh Mostafid, Benjamin Pradere, Bas W.G. van Rhijn, Shahrokh F. Shariat, Bhavan P. Rai, Francesco Soria, Viktor Soukup, Robbert G. Wood, Evanguelos N. Xylinas, Alexandra Masson-Lecomte, and Paolo Gontero

Subjects
Urology
Published
2023
Full Text
View/download PDF

26. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Author

Rouprêt, Morgan, primary, Seisen, Thomas, additional, Birtle, Alison J., additional, Capoun, Otakar, additional, Compérat, Eva M., additional, Dominguez-Escrig, José L., additional, Gürses Andersson, Irene, additional, Liedberg, Fredrik, additional, Mariappan, Paramananthan, additional, Hugh Mostafid, A., additional, Pradere, Benjamin, additional, van Rhijn, Bas W.G., additional, Shariat, Shahrokh F., additional, Rai, Bhavan P., additional, Soria, Francesco, additional, Soukup, Viktor, additional, Wood, Robbert G., additional, Xylinas, Evanguelos N., additional, Masson-Lecomte, Alexandra, additional, and Gontero, Paolo, additional

Published
2023
Full Text
View/download PDF

27. Survival analysis of patients with T1LG bladder cancer treated with BCG immunotherapy

Author

Krajewski, W., primary, Subiela, J.D., additional, Piszczek, R., additional, Del Giudice, F., additional, Nowak, Ł., additional, Chorbińska, J., additional, Moschini, M., additional, Masson-Lecomte, A., additional, Bebane, S., additional, Cimadamore, A., additional, Grobet-Jeandin, E., additional, Rouprêt, M., additional, D’andrea, D., additional, Mastroianni, R., additional, Gutierrez Hidalgo, B., additional, Gomez Rivas, J., additional, Mori, K., additional, Soria, F., additional, Laukhtina, E., additional, Carrion, D.M., additional, Akand, M., additional, Pradere, B., additional, Małkiewicz, B., additional, and Szydełko, T., additional

Published
2023
Full Text
View/download PDF

28. Cistoprostatectomia totale con o senza uretrectomia laparotomica

Author

François Desgrandchamps, R. de Petriconi, Alexandra Masson-Lecomte, A. Goujon, and Paul Meria

Subjects
General Medicine
Abstract

Riassunto La cistectomia totale accompagnata da una dissecazione linfonodale e il trattamento standard per i tumori della vescica che invadono il muscolo. E una procedura semplice, a patto di comprendere e rispettare l’anatomia chirurgica del bacino. Includere i pazienti nei protocolli di riabilitazione migliorata dopo l’intervento chirurgico (RAAC) riduce la morbilita di questa procedura. La tecnica chirurgica deve essere quanto piu standardizzata possibile al fine di ridurre al massimo il tempo operatorio e la perdita di sangue. Una conoscenza approfondita dell’anatomia della prostata e dell’uretra e essenziale per preservare l’uretra in vista della sostituzione della vescica. L’utilizzo di sistemi di termofusione tissutale ha rivoluzionato la dissecazione e l’emostasi dei peduncoli vascolari vescicali e prostatici in assenza di conservazione nervosa. La dissecazione linfonodale e una parte fondamentale dell’operazione e deve rispettare i limiti anatomici della dissecazione estesa. L’uretrectomia non e di routine, ma deve essere presa in considerazione in caso di tumore esteso all’uretra prostatica. La tecnica per via prepubica evita un’ulteriore incisione perineale e riduce la morbilita.

Published
2021
Full Text
View/download PDF

29. Résultats oncologiques de la thermo-chimiothérapie par HIVEC pour tumeurs de vessie réfractaires au BCG : base française multicentrique HIVEC-France

Author

Pignot, G., primary, Masson-Lecomte, A., additional, Chamouni, A., additional, Baboudjian, M., additional, Lechevallier, E., additional, Lebacle, C., additional, Irani, J., additional, Tillou, X., additional, Waeckel, T., additional, Monges, A., additional, Doisy, L., additional, Mourey, E., additional, and Duperron, C., additional

Published
2022
Full Text
View/download PDF

32. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

Beijert, I.J., primary, Hentschel, A.E., additional, Bründl, J., additional, Compérat, E.M, additional, Plass, K., additional, Rodríguez, O., additional, Subiela Henríquez, J.D., additional, Hernández, V., additional, De La Peña, E., additional, Alemany, I., additional, Turturica, D., additional, Pisano, F., additional, Soria, F., additional, Čapoun, O., additional, Bauerová, L., additional, Pešl, M., additional, Bruins, H.M., additional, Runneboom, W., additional, Herdegen, S., additional, Breyer, J., additional, Brisuda, A., additional, Calatrava, A., additional, Rubio-Briones, J.., additional, Seles, M., additional, Mannweiler, S., additional, Bosschieter, J., additional, Kusuma, V.R.M., additional, Ashabere, D., additional, Huebner, N., additional, Cotte, J., additional, Mertens, L.S, additional, Masson-Lecomte, A., additional, Liedberg, F., additional, Cohen, D., additional, Lunelli, L., additional, Cussenot, O., additional, El Sheikh, S., additional, Volanis, D., additional, Côté, J., additional, Rouprêt, M., additional, Haitel, A., additional, Shariat, S.F., additional, Mostafid, A.H., additional, Nieuwenhuijzen, J.A., additional, Zigeuner, R., additional, Dominguez-Escrig, J.L., additional, Hacek, J., additional, Zlotta, A.R., additional, Burger, M., additional, Evert, M., additional, Hulsbergen - Van De Kaa, C.A., additional, Van Der Heijden, A.G., additional, Kiemeney, L.A.L.M., additional, Soukup, V., additional, Molinaro, L., additional, Gontero, P., additional, Llorente, C., additional, Algaba, F., additional, Palou, J., additional, N’Dow, J., additional, Ribal, M.J., additional, Van Der Kwast, T.H., additional, Babjuk, M., additional, Sylvester, R.J., additional, and Van Rhijn, B.W.G., additional

Published
2022
Full Text
View/download PDF

34. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum

Author

Beijert, Irene J., primary, Hentschel, Anouk E., additional, Bründl, Johannes, additional, Compérat, Eva M., additional, Plass, Karin, additional, Rodríguez, Oscar, additional, Subiela Henríquez, Jose D., additional, Hernández, Virginia, additional, de la Peña, Enrique, additional, Alemany, Isabel, additional, Turturica, Diana, additional, Pisano, Francesca, additional, Soria, Francesco, additional, Čapoun, Otakar, additional, Bauerová, Lenka, additional, Pešl, Michael, additional, Maxim Bruins, H., additional, Runneboom, Willemien, additional, Herdegen, Sonja, additional, Breyer, Johannes, additional, Brisuda, Antonin, additional, Calatrava, Ana, additional, Rubio-Briones, José, additional, Seles, Maximilian, additional, Mannweiler, Sebastian, additional, Bosschieter, Judith, additional, Kusuma, Venkata R.M., additional, Ashabere, David, additional, Huebner, Nicolai, additional, Cotte, Juliette, additional, Mertens, Laura S., additional, Masson-Lecomte, Alexandra, additional, Liedberg, Fredrik, additional, Cohen, Daniel, additional, Lunelli, Luca, additional, Cussenot, Olivier, additional, El Sheikh, Soha, additional, Volanis, Dimitrios, additional, Côté, Jean-François, additional, Rouprêt, Morgan, additional, Haitel, Andrea, additional, Shariat, Shahrokh F., additional, Mostafid, A. Hugh, additional, Nieuwenhuijzen, Jakko A., additional, Zigeuner, Richard, additional, Dominguez-Escrig, Jose L., additional, Hacek, Jaromir, additional, Zlotta, Alexandre R., additional, Burger, Maximilian, additional, Evert, Matthias, additional, Hulsbergen-van de Kaa, Christina A., additional, van der Heijden, Antoine G., additional, A.L.M. Kiemeney, Lambertus, additional, Soukup, Viktor, additional, Molinaro, Luca, additional, Gontero, Paolo, additional, Llorente, Carlos, additional, Algaba, Ferran, additional, Palou, Joan, additional, N'Dow, James, additional, Ribal, Maria J., additional, van der Kwast, Theo H., additional, Babjuk, Marko, additional, Sylvester, Richard J., additional, and van Rhijn, Bas.W.G., additional

Published
2022
Full Text
View/download PDF

35. Survival analysis of patients with T1LG bladder cancer treated with BCG immunotherapy

Author

W. Krajewski, J.D. Subiela, R. Piszczek, F. Del Giudice, Ł. Nowak, J. Chorbińska, M. Moschini, A. Masson-Lecomte, S. Bebane, A. Cimadamore, E. Grobet-Jeandin, M. Rouprêt, D. D’andrea, R. Mastroianni, B. Gutierrez Hidalgo, J. Gomez Rivas, K. Mori, F. Soria, E. Laukhtina, D.M. Carrion, M. Akand, B. Pradere, B. Małkiewicz, and T. Szydełko

Subjects
Urology
Published
2023
Full Text
View/download PDF

36. International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members

Author

I.J. Beijert, L. Cheng, F. Liedberg, K. Plass, P. Gontero, M.J. Ribal, M. Babjuk, P.C. Black, A.M. Kamat, F. Algaba, D.M. Berman, A. Hartmann, A. Masson-Lecomte, M. Rouprêt, A. Lopez-Beltran, S.F. Shariat, H. Mostafid, M. Burger, J. Palou, E.M. Compérat, R.J. Sylvester, B.W.G. Van Rhijn, and M. Downes

Subjects
Urology
Published
2023
Full Text
View/download PDF

37. Cistoprostatectomía total con o sin uretrectomía por laparotomía

Author

A. Goujon, R. de Petriconi, François Desgrandchamps, Alexandra Masson-Lecomte, and Paul Meria

Subjects
03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, 030232 urology & nephrology, General Medicine
Abstract

Resumen La cistectomia total asociada a un vaciamiento ganglionar es el tratamiento de referencia de los tumores de vejiga con invasion muscular. Se trata de una intervencion simple, siempre que se conozca y se respete la anatomia quirurgica de la pelvis. La inclusion de los pacientes en protocolos de rehabilitacion mejorada posquirurgica (RMPQ) permite reducir la morbilidad de este procedimiento. La tecnica quirurgica debe ser lo mas estandarizada posible para reducir al maximo la duracion de la intervencion y la perdida de sangre. El conocimiento perfecto de la anatomia prostatica y uretral es indispensable para la preservacion de la uretra con vistas a un reemplazo vesical. La utilizacion de sistemas de termofusion tisular ha revolucionado la diseccion y la hemostasia de los pediculos vasculares vesicales y prostaticos en ausencia de preservacion nerviosa. El vaciamiento ganglionar es un tiempo fundamental de la intervencion y debe respetar los limites anatomicos del vaciamiento ampliado. La uretrectomia no se realiza de forma sistematica, pero debe plantearse en los tumores ampliados a la uretra prostatica. La tecnica por via prepubica evita una incision perineal suplementaria y disminuye la morbilidad.

Published
2021
Full Text
View/download PDF

38. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration

Author

Lonati, Chiara, primary, Baumeister, Philipp, additional, Afferi, Luca, additional, Mari, Andrea, additional, Minervini, Andrea, additional, Krajewski, Wojciech, additional, Azizi, Sosan, additional, Hendricksen, Kees, additional, Martini, Alberto, additional, Necchi, Andrea, additional, Montorsi, Francesco, additional, Briganti, Alberto, additional, Colombo, Renzo, additional, Tafuri, Alessandro, additional, Antonelli, Alessandro, additional, Cerruto, Maria Angela, additional, Rouprêt, Morgan, additional, Masson-Lecomte, Alexandra, additional, Laukhtina, Ekaterina, additional, D’Andrea, David, additional, Shariat, Shahrokh F., additional, Soria, Francesco, additional, Marra, Giancarlo, additional, Gontero, Paolo, additional, Contieri, Roberto, additional, Hurle, Rodolfo, additional, Valiquette, Anne Sophie, additional, Mir, M. Carmen, additional, Zamboni, Stefania, additional, Simeone, Claudio, additional, Klatte, Tobias, additional, Teoh, Jeremy Yuen-Chun, additional, Yoshida, Soichiro, additional, Fujii, Yasuhisa, additional, Carando, Roberto, additional, Schulz, Gerald B., additional, Mordasini, Livio, additional, Mattei, Agostino, additional, and Moschini, Marco, additional

Published
2022
Full Text
View/download PDF

39. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : tumeurs de la vessie

Author

Mathieu Roumiguié, S. Brunelle, Alexandra Masson-Lecomte, Evanguelos Xylinas, Morgan Rouprêt, A. Mejean, Eva Compérat, Stéphane Larré, Nadine Houede, Y. Neuzillet, F. Audenet, and Géraldine Pignot

Subjects
Chemotherapy, medicine.medical_specialty, Bladder cancer, business.industry, Urology, medicine.medical_treatment, Urinary diversion, 030232 urology & nephrology, Cancer, Pembrolizumab, medicine.disease, Ureterostomy, Cystectomy, 03 medical and health sciences, 0302 clinical medicine, medicine, business, Contraindication
Abstract

Summary Objective. - To update French guidelines for the management of bladder cancer specifically non-muscle invasive (NMIBC) and muscle-invasive bladder cancers (MIBC). Methods. - A Medline search was achieved between 2018 and 2020, notably regarding diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. Results. - Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumor. The use of fluorescence and a second-look indication are essential to improve initial diagnosis. Risks of both recurrence and progression can be estimated using the EORTC score. A stratification of patients into low, intermediate and high risk groups is pivotal for recommending adjuvant treatment: instillation of chemotherapy (immediate post-operative, standard schedule) or intravesical BCG (standard schedule and maintenance). Cystectomy is recommended in BCG-refractory patients. Extension evaluation of MIBC is based on contrast-enhanced pelvic-abdominal and thoracic CT-scan. Multiparametric MRI can be an alternative. Cystectomy associated with extended lymph nodes dissection is considered the gold standard for non-metastatic MIBC. It should be preceded by cisplatin-based neoadjuvant chemotherapy in eligible patients. An orthotopic bladder substitution should be proposed to both male and female patients with no contraindication and in cases of negative frozen urethral samples; otherwise transileal ureterostomy is recommended as urinary diversion. All patients should be included in an Early Recovery After Surgery (ERAS) protocol. For metastatic MIBC, first-line chemotherapy using platin is recommended (GC or MVAC), when performans status (PS 60 mL/min) allow it (only in 50% of cases). In second line treatment, immunotherapy with pembrolizumab demonstrated a significant improvement in overall survival. Conclusion. - These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment of patients diagnosed with NMIBC and MIBC.

Published
2020
Full Text
View/download PDF

40. Recommandations françaises du Comité de cancérologie de l’AFU - actualisation 2020–2022 : tumeurs de la voie excrétrice urinaire supérieure

Author

Yann Neuzillet, Evanguelos Xylinas, Alexandra Masson-Lecomte, Morgan Rouprêt, Mathieu Roumiguié, Eva Compérat, Stéphane Larré, A. Mejean, S. Brunelle, Nadine Houede, François Audenet, and Géraldine Pignot

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Urology, Gold standard, 030232 urology & nephrology, MEDLINE, Cancer, Evidence-based medicine, medicine.disease, 03 medical and health sciences, Bassinet, 0302 clinical medicine, Ureter, medicine.anatomical_structure, Medicine, Ureteroscopy, business, Renal pelvis
Abstract

summary Introduction. –The purpose was to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC). Methods. – A systematic Medline search was performed between 2018 and 2020, as regards diagnosis, options of treatment and follow-up of UTUC, to evaluate different references with levels of evidence. Results. – The diagnosis of this rare pathology is based on CT-scan acquisition during excretion and ureteroscopy with histological biopsies. Radical nephroureterectomy (RNU) remains the gold standard for surgical treatment, nevertheless a conservative endoscopic approach can be proposed for low risk lesion: unifocal tumor, possible complete resection and low grade and absence of invasion on CT-scan. Close monitoring with endoscopic follow-up (flexible ureteroscopy) in compliant patients is therefore necessary. After RNU, bladder instillation of chemotherapy is recommended to reduce risk of bladder recurrence. A systemic chemotherapy is recommended after RNU in pT2–T4 N0–3 M0 disease. Conclusion. – These updated guidelines will contribute to increase the level of urological care for diagnosis and treatment for UTUC.

Published
2020
Full Text
View/download PDF

41. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway

Author

Dobé, T.-R., primary, Belhadj, Y., additional, Michel, C., additional, Djouadou, M., additional, Bouchardi, A., additional, Liron, C., additional, Bento, C., additional, Aregui, A., additional, Meria, P., additional, Thevenot, A., additional, Plaud, B., additional, Culine, S., additional, Mongiat-Artus, P., additional, Desgrandchamps, F., additional, and Masson-Lecomte, A., additional

Published
2022
Full Text
View/download PDF

42. Instauration du traitement adjuvant endovésical par épirubicine des tumeurs de vessie n’infiltrant pas le muscle : premier retour national d’expérience du CC-AFU vessie

Author

Rollin, P., primary, Xylinas, E., additional, Lanz, C., additional, Audenet, F., additional, Brunelle, S., additional, Compérat, E., additional, Houédé, N., additional, Larré, S., additional, Masson-Lecomte, A., additional, Pignot, G., additional, Roumiguié, M., additional, Méjean, A., additional, Rouprêt, M., additional, and Neuzillet, Y., additional

Published
2022
Full Text
View/download PDF

43. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

Author

Leon, P., primary, Saint, F., additional, Audenet, F., additional, Roumiguié, M., additional, Allory, Y., additional, Loriot, Y., additional, Masson-Lecomte, A., additional, Pradère, B., additional, Seisen, T., additional, Traxer, O., additional, Xylinas, E., additional, Roupret, M., additional, and Neuzillet, Y., additional

Published
2022
Full Text
View/download PDF

44. Hématurie microscopique, gestion et attitude clinique en 2021

Author

A. Masson-Lecomte

Subjects
03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology
Abstract

Resume L’hematurie microscopique est un motif frequent de consultation en Urologie et concerne des populations de tous âges. Les benefices du bilan (identifier une pathologie urologique et en particulier un carcinome urothelial) doivent etre mis en perspective des risques potentiels (infection urinaire, irradiation). Tout venant, le risque de retrouver un cancer chez un patient adresse pour une hematurie microscopique est de l’ordre de 3 %. Cependant, plusieurs facteurs ont ete clairement identifies comme associes a la decouverte d’une neoplasie de l’appareil urinaire tels que l’âge, le sexe, le tabagisme ou les symptomes associes. Les recommandations europeennes et americaines sont en faveur d’une abstention d’examens invasifs ou irradiants chez les patients de moins de 40 ans. Apres 40 ans, il est possible de classer les patients en groupes de risque et d’adapter le bilan etiologique. Les patients de plus de 60 ans et/ou presentant des facteurs de risque doivent imperativement beneficier d’une cystoscopie, d’une cytologie urinaire et d’un uroscanner.

Published
2021
Full Text
View/download PDF

46. Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG

Author

Audenet, F., primary, Sotto, A., additional, Roumiguié, M., additional, Allory, Y., additional, Andrejak, C., additional, Leon, P., additional, Loriot, Y., additional, Masson-Lecomte, A., additional, Pradère, B., additional, Seisen, T., additional, Traxer, O., additional, Xylinas, E., additional, Bruyère, F., additional, Roupret, M., additional, Saint, F., additional, and Neuzillet, Y., additional

Published
2022
Full Text
View/download PDF

47. RE-TUR + BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: A feasibility phase of a randomized controlled study

Author

Soria, F., primary, Rosazza, M., additional, Burger, M., additional, Comperat, E., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Mostafid, H., additional, Van Rhijn, B.W., additional, Shariat, S.F., additional, Babjuk, M., additional, Sylvester, R.J., additional, Palou, J., additional, and Gontero, P., additional

Published
2022
Full Text
View/download PDF

48. Transcriptomic profiling of upper tract urothelial carcinoma: Utility of the consensus molecular classification of bladder cancer, differential immune signatures and molecular heterogeneity

Author

Fontugne, J., primary, Xylinas, E., additional, Krucker, C., additional, Dixon, V., additional, Groeneveld, C.S., additional, Pinar, H., additional, Califano, G., additional, Bucau, M., additional, Verine, J., additional, Desgrandchamps, F., additional, Hermieu, J.F., additional, Radvanyi, F., additional, Allory, Y., additional, and Masson-Lecomte, A., additional

Published
2022
Full Text
View/download PDF

49. Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups

Author

Gontero, P., primary, Dominguez-Escrig, J.L., additional, Van Rhijn, B.W.G., additional, Mostafid, A.H., additional, Roupret, M., additional, Cohen, D., additional, Comperat, E., additional, Liedberg, F., additional, Palou Redorta, J., additional, Burger, M., additional, Shariat, S., additional, Seisen, T., additional, Soukup, V., additional, Masson-Lecomte, A., additional, Capoun, O., additional, Babjuk, M., additional, and Sylvester, R.J., additional

Published
2022
Full Text
View/download PDF

50. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Author

Babjuk, Marko, primary, Burger, Maximilian, additional, Capoun, Otakar, additional, Cohen, Daniel, additional, Compérat, Eva M., additional, Dominguez Escrig, José L., additional, Gontero, Paolo, additional, Liedberg, Fredrik, additional, Masson-Lecomte, Alexandra, additional, Mostafid, A. Hugh, additional, Palou, Joan, additional, van Rhijn, Bas W.G., additional, Rouprêt, Morgan, additional, Shariat, Shahrokh F., additional, Seisen, Thomas, additional, Soukup, Viktor, additional, and Sylvester, Richard J., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results